Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population Part II

This study has been completed.

Sponsors and Collaborators:	Lawson Health Research Institute Eli Lilly and Company Regional Mental Health Care, London
Information provided by:	Lawson Health Research Institute
ClinicalTrials.gov Identifier:	NCT00377117

Purpose

The purpose of this study is to learn more about the relationship between serious mental illness and the detection and management of diabetes and pre-diabetic conditions. Patients who have been diagnosed with schizophrenia are at an increased risk for developing diabetes and pre-diabetic conditions such as impaired glucose tolerance and impaired fasting glucose. In addition, novel antipsychotics have also been linked to impaired glucose metabolism and increased incidence of diabetes. The medical management of these patients may be difficult ot achieve through standard family practice. The objectives of this project are to: screen a sample of this high-risk population using an Oral Glucose Tolerance Test (OGTT), and to provide multidisciplinary team support to those identified as having diabetes or a pre-diabetic condition.

Condition	Intervention	Phase
Diabetes Mellitus Schizophrenia Psychotic Disorders	Procedure: Management Procedure: Screening	Phase I Phase II

MedlinePlus related topics: Diabetes Mental Health Psychotic Disorders Schizophrenia

U.S. FDA Resources

Study Type:	Observational
Study Design:	Screening, Longitudinal, Defined Population, Retrospective/Prospective Study
Official Title:	Diabetes Screening, Risk Management, and Disease Management in a High-Risk Mental Health Population.

Further study details as provided by Lawson Health Research Institute:

Enrollment:	39
Study Start Date:	May 2006
Study Completion Date:	July 2007

Show Detailed Description

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients active in current Regional Mental Health Care London, Specialized Adult London Ambulatory Care and Assertive Community Treatment programs with known diagnosis of a Psychotic Disorder and/or use of Novel Antipsychotics.
Must have family physician contact and ability to consent to medical care.

Exclusion Criteria:

Any patient with declaration on file stating incapable of consenting to medical treatment.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00377117

Locations

Canada, Ontario
Regional Mental Health Care London
London, Ontario, Canada, N6A 4H1

Sponsors and Collaborators

Lawson Health Research Institute

Eli Lilly and Company

Regional Mental Health Care, London

Investigators

Principal Investigator:	Stewart B Harris, MD MPH CCFP FACPM	Centre for Studies in Family Medicine
Principal Investigator:	David RS Haslam, MSc MD FRCPC	Regional Mental Health Care, London

More Information

Publications:

Crews C, Batal H, Elasy T, Casper E, Mehler PS. Primary care for those with severe and persistent mental illness. West J Med. 1998 Oct;169(4):245-50.

Brown JB, Lent B, Stirling A, Takhar J, Bishop J. Caring for seriously mentally ill patients. Qualitative study of family physicians' experiences. Can Fam Physician. 2002 May;48:915-20.

Kushner K, Diamond R, Beasley JW, Mundt M, Plane MB, Robbins K. Primary care physicians' experience with mental health consultation. Psychiatr Serv. 2001 Jun;52(6):838-40.

Study ID Numbers:	R-05-470
Study First Received:	September 14, 2006
Last Updated:	July 20, 2007
ClinicalTrials.gov Identifier:	NCT00377117
Health Authority:	Canada: Health Canada

Study placed in the following topic categories:

Schizophrenia
Metabolic Diseases
Mental Disorders
Diabetes Mellitus
Endocrine System Diseases

Psychotic Disorders
Endocrinopathy
Metabolic disorder
Glucose Metabolism Disorders
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on January 15, 2009